NCT01930396 (HEMO-TIN) is a Phase 4 clinical trial of Tinzaparin in Kidney Failure, Chronic, sponsored by Christine Ribic.

Who is sponsoring NCT01930396?

NCT01930396 is sponsored by Christine Ribic.

What drugs are being tested in NCT01930396?

Interventions in NCT01930396: Tinzaparin, Unfractionated Heparin, Placebo (for Tinzaparin), Placebo (for Unfractionated Heparin).

What condition does NCT01930396 study?

NCT01930396 studies Kidney Failure, Chronic.

Is NCT01930396 still recruiting?

NCT01930396 is currently completed. Last updated 12 October 2016.

Last reviewed 2016-10-12 · How we verify

NCT01930396: HEMO-TIN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intermittent HEMOdialysis Anticoagulation With TINzaparin Versus Unfractionated Heparin: A Pilot Multicentre Randomized Controlled Trial (HEMO-TIN Trial)

Completed Phase 4 Last updated 12 October 2016

What this trial tests

Phase 4 trial testing Tinzaparin in Kidney Failure, Chronic in 191 participants. Completed in 1 September 2016.

Timeline

1 September 2013

Primary endpoint
1 September 2016

1 September 2016

Quick facts

Lead sponsor	Christine Ribic
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	prevention
Enrollment	191
Start date	1 September 2013
Primary completion	1 September 2016
Estimated completion	1 September 2016
Sites	1 location across Canada

Drugs / interventions tested

Tinzaparin — full drug profile →
Unfractionated Heparin — full drug profile →
Placebo (for Tinzaparin) — full drug profile →
Placebo (for Unfractionated Heparin) — full drug profile →

Conditions studied

Kidney Failure, Chronic — all drugs for Kidney Failure, Chronic →

Sponsor

Christine Ribic — full company profile →

Who can join

18 and older, any sex, with Kidney Failure, Chronic. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Rate of major, clinically important non-major or minor bleeding
Time frame: 26 weeks

Sponsor's own description

The HEMO-TIN trial is designed to look at both the safety (bleeding risk) and effectiveness (clotting risk) of tinzaparin compared with unfractionated heparin for anticoagulation in hemodialysis patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Tinzaparin

Trials testing the same drug.

NCT05625932 — TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer · Phase 3 · completed
NCT07361679 — LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention · Phase 4 · recruiting
NCT04730856 — Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 P · NA · completed
NCT03240120 — A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism · Phase 3 · unknown
NCT02719418 — Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses · completed

Other recruiting trials for Kidney Failure, Chronic

Currently open trials in the same condition.

NCT06903559 — Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients · Phase 1, PHASE2 · recruiting
NCT06438445 — Effects of Royal Jelly Supplementation in Chronic Kidney Disease · NA · recruiting
NCT06288451 — DePTH: De-emphasize PTH · Phase 2 · active not recruiting
NCT05968391 — Acetoacetate and Acetate Metabolism in Patients With Chronic Kidney Failure.(RENO-TEP) · recruiting
NCT06314503 — First-in-human Study to Examine Safety of a New Peritoneal Dialysis Device (WEAKID) in End-stage Kidney Disease Patients · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01930396 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Christine Ribic
Last refreshed: 12 October 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01930396.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing